Stada Australia BioQ deal

STADA Pharmaceuticals Australia Pty Ltd has announced a new agreement with San Franciscobased BioY Pharma Incorporated for the commercialisation of three ready-to-use infusion pharmaceuticals in Australia and New Zealand.

The collaboration includes Ropivacaine ReadyFusOR, an opioid sparing post-surgical pain therapy as well as two other product candidates.

Ropivacaine ReadyFusOR, which was recently approved by the Therapeutic Goods Administration, is a single-use infusion product which is pre-filled with 0.2% Ropivacaine, activated by a single touch at the point of care.

Stada Australia managing director Gary Clark said the company welcomed the opportunity to partner with BioQ to launch the products locally.

“The addition of these exciting products to our portfolio will enhance our reputation as a provider of quality healthcare, leading to improved patient outcomes,” he said.

Stada Australia is a wholly-owned subsidiary of publicly listed German pharmaceutical manufacturer Stada Arzneimittle AG which employs almost 11,000 people worldwide.

BioQ Pharma is a privately held specialty pharmaceutical company which focuses on developing and commercialising ready-to-use infusible pharmaceuticals via its proprietary unit-dose systems.